Xenetic Biosciences reported Q3 losses of $(0.69) per share, beating the analyst consensus estimate of $(1.12) by 38.39 percent. This is a 15 percent decrease over losses from the same period last year. The company also reported quarterly sales of $611.17 thousand, beating the analyst consensus estimate of $460.00 thousand by 32.86 percent, a 47.54 percent increase over sales from the same period last year.